Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications.
about
Huntington's disease: a clinical review.Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's diseaseA broad phenotypic screen identifies novel phenotypes driven by a single mutant allele in Huntington's disease CAG knock-in mice.Neuroendocrine disturbances in Huntington's diseaseFormation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.Microcirculation response to local cooling in patients with Huntington's disease.Electroconvulsive shock ameliorates disease processes and extends survival in huntingtin mutant mice.Hypothalamic microinflammation: a common basis of metabolic syndrome and aging.Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?A 24-Hour Study of the Hypothalamo-Pituitary Axes in Huntington's Disease.Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy.A Metabolic Study of Huntington's Disease.Expression of mutant huntingtin in leptin receptor-expressing neurons does not control the metabolic and psychiatric phenotype of the BACHD mouseSuprachiasmatic nucleus neuropeptide expression in patients with Huntington's Disease.Abnormal Weight and Body Mass Index in Children with Juvenile Huntington's Disease.Weight variation before and after surgery in Parkinson's disease: a noradrenergic modulation?Hypothalamic alterations in Huntington's disease patients: comparison with genetic rodent models.Ghrelin rescues skeletal muscle catabolic profile in the R6/2 mouse model of Huntington's diseaseWhole gene expression profile in blood reveals multiple pathways deregulation in R6/2 mouse model.Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington's disease.Neuropeptide alterations in the infundibular nucleus of Huntington's disease patients.Leptin secretion rate increases with higher CAG repeat number in Huntington's disease patients.Autonomic dysfunction in presymptomatic and early symptomatic Huntington's disease.Functional increase of brain histaminergic signaling in Huntington's disease.Paraventricular nucleus neuropeptide expression in Huntington's disease patients.Regulation of Hippocampal Synaptic Function by the Metabolic Hormone, Leptin: Implications for Health and Neurodegenerative DiseaseStudying Huntington's Disease in Yeast: From Mechanisms to Pharmacological Approaches
P2860
Q21202876-1A13E80F-05F9-4D94-9DB4-4D53827AD474Q24647189-0316CC20-DEAA-472A-A39B-852E19DE246AQ28391627-D9C02434-4DC8-46C7-BD71-9FD717F445DEQ33421708-0129BB26-A5D4-4605-BB52-FF7F44AAB631Q33517121-70EB450D-4FDA-4C1A-BE5D-75515B8CFF1FQ34052018-A9111055-25C2-4CA3-866D-E7E30374BEB1Q34505628-34490DE5-D577-44E8-A42F-069729290D59Q34808934-8DD3AC8E-3282-4C9D-BD74-8F8788FEBB4AQ35158376-2FDE0910-8DD9-4E2D-B306-37ED24E548FCQ35797126-8FC63AB2-D699-4F75-9C78-6B23B3BF8EFBQ36234711-E0674904-5F1E-4A7C-8337-0F0F0F1036DCQ36445216-E0C701FB-A99E-4FE0-BE21-D3417B17B567Q36459384-2B1A13AB-736C-4494-8C09-E9904BA493DEQ36473222-DEC14BFD-5601-4F5D-AFBD-FCA8E671BDB1Q36950717-CA217C2E-B48A-4025-BD7D-E94DC2C08DC8Q38018884-F9FDADA8-4109-4DB5-86A1-A6B7DEDE011CQ38235229-167EF578-D15B-436B-9594-9A6462CD7BD4Q42577971-80B11E2D-5682-40D4-B4AA-33C78BBE8079Q42918972-B7C1629D-8CC9-42B6-959E-B85D9A08BE87Q43314674-3F94DCEA-83AC-410C-B78C-CA3A91C10CB8Q45289739-A91FD4F6-79B1-4B55-85D4-622A8355C8F0Q45294241-253FA553-FCB9-4D73-A97C-EE5361758A3CQ45296254-36D36DFA-83A6-4B61-9489-2B1DB440BFCCQ45300658-307B233E-6CBD-4A9A-BE4E-8BA1FDB509CFQ45305979-4DB553A9-BC13-42BB-8579-DFFDFE03591DQ58553488-11A89FCA-DBA2-43D3-984B-41B68CF2767BQ58764761-8B8B132C-0415-427D-9FEF-76722DD20A4F
P2860
Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hypothalamic dysfunction and n ...... and therapeutic implications.
@en
Hypothalamic dysfunction and n ...... and therapeutic implications.
@nl
type
label
Hypothalamic dysfunction and n ...... and therapeutic implications.
@en
Hypothalamic dysfunction and n ...... and therapeutic implications.
@nl
prefLabel
Hypothalamic dysfunction and n ...... and therapeutic implications.
@en
Hypothalamic dysfunction and n ...... and therapeutic implications.
@nl
P2860
P1476
Hypothalamic dysfunction and n ...... s and therapeutic implications
@en
P2093
P2860
P304
P356
10.1515/REVNEURO.2007.18.3-4.223
P577
2007-01-01T00:00:00Z